(Q28166022)

https://api.crossref.org/works/10.1016/S1388-9842(03)00161-2

30 March 2024

2

John G. F. Cleland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607210

30 March 2024

3

Nick Freemantle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607210

30 March 2024

author name string

Huan Loh

4

0 references

Anwar Memon

5

0 references

Alison P. Coletta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607210

30 March 2024

Andrew L. Clark

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607210

full work available at URL

30 March 2024

language of work or name

English

0 references

publication date

October 2003

0 references

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/S1388-9842%2803%2900161-2

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607210

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1016%2FS1388-9842(03)00161-2

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1388-9842(03)00161-2

https://onlinelibrary.wiley.com/doi/pdf/10.1016/S1388-9842%2803%2900161-2

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1388-9842(03)00161-2

European Journal of Heart Failure

30 March 2024

published in

0 references

volume

5

0 references

issue

5

0 references

page(s)

697-704

0 references

cites work

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) pro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

The safety and tolerability of candesartan cilexetil in CHF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

A strategy to reduce cardiovascular disease by more than 80%

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Warfarin, aspirin, or both after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Diastolic heart failure: neglected or misdiagnosed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900161-2

Polypharmacy (or polytherapy) in the treatment of heart failure

21 January 2018

14

1 reference

https://api.crossref.org/works/10.1016/S1388-9842(03)00161-2

30 March 2024

Identifiers

release_3g6nyyhgqzbclelh45nrkw5usm

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3g6nyyhgqzbclelh45nrkw5usm

mapped directly with Wikidata item

24 November 2022

based on heuristic